Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and blaOXA gene status

Pharmacotherapy

Volumn 30, Issue 4, 2010, Pages 354-360

  Esterly, John S ^a,b   Qi, Chao ^c   Malczynski, Michael ^b   Scheetz, Marc H ^a,b  

^a MIDWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acinetobacter baumannii; blaOXA; Carbapenem hydrolyzing oxacillinase genes; Carbapenems; Doripenem; Susceptibility

Indexed keywords

CARBAPENEM; DORIPENEM; IMIPENEM; MEROPENEM;

ACCURACY; ACINETOBACTER BAUMANNII; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLA OXA GENE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENOTYPE; GOLD STANDARD; IN VITRO STUDY; NONHUMAN; POLYMERASE CHAIN REACTION;

ACINETOBACTER BAUMANNII; BETA-LACTAMASES; CARBAPENEMS; GENOTYPE; HOSPITALS; HUMANS; IMIPENEM; OXYTOCIN; POLYMERASE CHAIN REACTION; THIENAMYCINS;

EID: 77950378914     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.4.354     Document Type: Article

References (34)

1. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008;358:1271-1281
2. Richet HM, Mohammed J, McDonald LC, Jarvis WR. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis 2001;7:319-322
3. Van Looveren M, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004;10:684-704.
4. Scheetz MH, Zembower TR, Bolon MK, et al. The increasing incidence of carbapenem intermediate or resistant Acinetobacter baumannii (CIRA): application of a simplified model to predict future carbapenem susceptibility among A. baumannii. Presented at the 44th annual meeting of the Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12-15, 2006.
5. Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006;50:2941-2945
6. Siegel RE. Emerging gram-negative antibiotic resistance: daunting challenges, declining sensitivities, and dire consequences. Respir Care 2008;53:471-479
7. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
8. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008;61:1369-1375
9. Lesho E, Wortmann G, Moran K, Craft D. Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility. Clin Infect Dis 2005;41:758-759
10. Jones RN, Sader HS, Fritsche TR, Rhomberg PR. Carbapenem susceptibility discords among Acinetobacter isolates [letter]. Clin Infect Dis 2006;42:158.
11. Ikonomidis A, Pournaras S, Maniatis AN, Legakis NJ, Tsakris A. Discordance of meropenem versus imipenem activity against Acinetobacter baumannii. Int J Antimicrob Agents 2006;28: 376-377
12. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-836
13. Qi C, Malczynski M, Parker M, Scheetz MH. Characterization of genetic diversity of carbapenem-resistant Acinetobacter baumannii clinical strains collected from 2004 to 2007. J Clin Microbiol 2008;46:1106-1109
14. Schreckenberger PC, Daneshvar MI, Hollis DG. Manual of clinical microbiology. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative gram-negative rods, vol 1, 9th ed. Washington, DC: ASM Press, 2007:770-802.
15. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19 (ISBN 1-56238-690-5). Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
17. Ortho-McNeil Phamaceutical, Inc. Doribax (doripenem injection) package insert. Raritan, NJ; 2007.
18. National Committee for Clincial Laboratory Standards. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline. NCCLS document M23-A2, 2nd ed. Wayne, PA: National Committee for Clinical Laboratory Standards, 2001.
19. Jones RN, Sader HS, Fritsche TR, Janechek MJ. Selection of a surrogate β-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis 2007;59:467-472
20. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005;49:3944-3947
21. Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. Pharmacokinetic- pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009;63:409-414
22. Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008;52:4388-4399
23. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004;48:3136-3140
24. Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 2009;63:426-433
25. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008;9:23-37.
26. Scheetz MH, Esterly JS, Malczynski M, Postelnick M, Qi C. Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2009;64:465-467
27. Ikawa K, Morikawa N, Uehara S, et al. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents 2009;33:276-279
28. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Carbapenems: EUACAST clinical MIC breakpoints, June 19, 2008, vol 2.0. Available from http://www.srga.org/eucastwt/MICTAB/MICcarbapenems.html. Accessed December 16, 2008.
29. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Doribax (doripenem injection), 2007. Johnson & Johnson Pharmaceutical Research & Development, LLC. Application No. 022106. Available from http://www.fda.gov/cder/foi/nda/2007/022106TOC.htm. Accessed December 16, 2008.
30. van Hal SJ, Wiklendt A, Espedido B, Ginn A, Iredell JR. Immediate appearance of plasmid-mediated resistance to multiple antibiotics upon antibiotic selection: an argument for systematic resistance epidemiology. J Clin Microbiol 2009;47:2325-2327
31. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007;44:87-93.
32. D'Arezzo S, Capone A, Petrosillo N, et al. Epidemic multidrug-resistant Acinetobacter baumannii related to European clonal types I and II in Rome (Italy). Clin Microbiol Infect 2009;15:347-357
33. Park YK, Choi JY, Jung SI, et al. Two distinct clones of carbapenem-resistant Acinetobacter baumannii isolates from Korean hospitals. Diagn Microbiol Infect Dis 2009;64:389-395
34. Qi C, Scheetz MH, Malczynski M. Characterization of Acinetobacter baumannii genotypes recovered from patients with repeated colonization or infection. Diagn Microbiol Infect Dis 2009;65:1-6.